Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
Cancers · 04.02.2024 · 16 (3) · 663
DOI: 10.3390/cancers16030663 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 04.02.2024. Verfasst von Qiao-Hong Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, California State University, Fresno, CA 93740, USA. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of Health, 2022 CSUPERB Research Development Award.
Abstract (Originalsprache)
Induced protein degradation has emerged as an innovative drug discovery approach, complementary to the classical method of suppressing protein function. The androgen receptor signaling pathway has been identified as the primary driving force in the development and progression of lethal castration-resistant prostate cancer. Since androgen receptor degraders function differently from androgen receptor antagonists, they hold the promise to overcome the drug resistance challenges faced by current therapeutics. Proteolysis-targeting chimeras (PROTACs), monomeric degraders, hydrophobic tagging, molecular glues, and autophagic degradation have demonstrated their capability in downregulating intracellular androgen receptor concentrations. The potential of these androgen receptor degraders to treat castration-resistant prostate cancer is substantiated by the advancement of six PROTACs and two monomeric androgen receptor degraders into phase I or II clinical trials. Although the chemical structures, in vitro and in vivo data, and degradation mechanisms of androgen receptor degraders have been reviewed, it is crucial to stay updated on recent advances in this field as novel androgen receptor degraders and new strategies continue to emerge. This review thus provides insight into recent advancements in this paradigm, offering an overview of the progress made since 2020.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, California State University, Fresno, CA 93740, USA.
ORCID-Profile: Qiao-Hong Chen, Erick Munoz
Förderung
- NIGMS NIH HHS
- National Institute of Health
- 2022 CSUPERB Research Development Award
- NIH
Zitieren
APA
Chen, Q. H., Munoz, E., & Ashong, D. (2024). Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer. Cancers, 16(3), 663. https://doi.org/10.3390/cancers16030663
Vancouver
Chen QH, Munoz E, Ashong D. Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer. Cancers. 2024;16(3):663. doi:10.3390/cancers16030663
BibTeX
@article{Chen2024,
author = {Chen, Qiao-Hong and Munoz, Erick and Ashong, Dennis},
title = {Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer},
journal = {Cancers},
year = {2024},
volume = {16},
number = {3},
pages = {663},
doi = {10.3390/cancers16030663}
}
EUVIMED